AMultiple sclerosis (MS) is chronic inflammatory disease that affecting the central nervous system (CNS) which leads to the degeneration of oligodendrocytes, neurons, and myelin over time. Being the foremost reason of neurological disability multiple sclerosis has affected about 2.5 million humans around the world. MS is mainly seen in early adulthood and adults in their middle age. Disease modifying agents are being used in treatment of relapsing multiple sclerosis. Medications that reduce the severity of the disease are frequently utilized as standard therapies. The immune system is the primary focus of modern MS treatments. However, researchers are putting more effort into designing novel CNS-focused treatments. Therefore, under the current scenario, an alternative route for drug delivery is required, one that provides a speedy onset of action and then maintains the drug release over an extended period. The desired prolong-acting intramuscular injecting stable fingolimod HCl microspheres to treat MS were formulated using solvent evaporation technique. Further, based on the number of factors to be optimized, formulation was prepared using solvent evaporation. Additionally, the formulated fingolimod microspheres were characterized for the size distribution of particle, particle surface morphology, and lyophilization of formulated microspheres. Post lyophilization, the formulated microspheres evaluation was done for efficiency of entrapment, drug release in-vitro, and stability parameters. Furthermore, in-vivo studies were performed on suitable animal models for the optimized formulation.